Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific increase in notional interest in American Depositary Shares (ADSs) by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific securities transaction rather than a financial results report.
| Metric | Value |
|---|---|
| Transaction Type | Dividend Re-investment |
| Instrument | American Depositary Shares (ADSs) |
| Transaction Price | $43.87 |
| Total Volume | 3,144.651 ADSs |
| Transaction Date | July 14, 2016 |
Material Changes
The filing details an increase in the notional interest of Mr. D E Troy (SVP & General Counsel) in the Company's ADSs. This change resulted from the re-investment of dividends paid to shareholders on July 14, 2016, under the Company's 2009 Performance Share Plan. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The scope is limited strictly to the notification of the PDMR transaction.
Investor Verification Points
- Verify the total volume of 3,144.651 ADSs acquired through dividend re-investment.
- Confirm the transaction price of $43.87 per ADS on July 14, 2016.
- Identify the specific plan (2009 Performance Share Plan) governing the transaction.
- Note that this filing does not contain quarterly or annual financial performance data.